%0 Journal Article
%T Two cardiac myosin inhibitors in the treatment of obstructive hypertrophic cardiomyopathy.
%A Desai MY
%A Braunwald E
%J Med
%V 5
%N 7
%D 2024 Jul 12
%M 39002536
暂无%R 10.1016/j.medj.2024.06.001
%X A key area of therapeutic progress in obstructive hypertrophic cardiomyopathy revolves around the emergence of cardiac myosin inhibitors, of which mavacamten and aficamten represent the first and second molecules. We summarize the key research evidence, including many similarities and potential differences between various clinical trials studying these molecules.